Celgene International Sàrl, a wholly owned subsidiary of Celgene
Corporation CELG, today presented results from the maintenance
phase of the TOUCHSTONE phase 2 clinical trial of Ozanimod, an
investigational compound, in patients with moderate to severe ulcerative
colitis at the United European Gastroenterology (UEG) Week in Barcelona,
Spain. This abstract was awarded a UEG Week Top Abstract Prize, which is
given to the top five abstracts submitted to UEG Week.
The TOUCHSTONE trial evaluated the efficacy and safety of 0.5 mg and 1
mg doses of Ozanimod compared with placebo after eight weeks of
treatment (induction phase) in 197 patients with moderate to severe
ulcerative colitis. The primary endpoint was the proportion of patients
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in